Royal Bank Of Canada Oramed Pharmaceuticals Inc. Transaction History

Royal Bank Of Canada

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.71 - $2.57 $6,790 - $10,205	3,971 Added 75.31%	9,244 $21,000
Q3 2023 Nov 14, 2023	BUY	$2.51 - $3.55 $13,235 - $18,719	5,273 New	5,273 $13,000
Q1 2023 May 15, 2023	SELL	$1.93 - $13.1 $3,860 - $26,200	-2,000 Reduced 16.67%	10,000 $21,000
Q4 2022 Feb 14, 2023	SELL	$6.21 - $12.03 $74,377 - $144,083	-11,977 Reduced 49.95%	12,000 $144,000
Q3 2022 Nov 14, 2022	BUY	$4.6 - $9.91 $3,380 - $7,283	735 Added 3.16%	23,977 $155,000

Q2 2022 Aug 15, 2022	BUY	$3.72 - $9.0 $28,458 - $68,850	7,650 Added 49.06%	23,242 $106,000
Q1 2022 May 16, 2022	SELL	$8.19 - $13.89 $30,409 - $51,573	-3,713 Reduced 19.23%	15,592 $135,000
Q4 2021 Feb 14, 2022	BUY	$12.98 - $29.75 $56,839 - $130,275	4,379 Added 29.34%	19,305 $276,000
Q3 2021 Nov 15, 2021	BUY	$12.13 - $23.82 $134,545 - $264,211	11,092 Added 289.31%	14,926 $328,000
Q2 2021 Aug 16, 2021	BUY	$8.34 - $14.59 $31,975 - $55,938	3,834 New	3,834 $51,000

5.69M

8.3K

2.7K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $97.1M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.